Salt Lake City, UTNCT06212323Now EnrollingIRB Ready

Smoldering Multiple Myeloma Clinical Trial in Salt Lake City, UT

Access cutting-edge smoldering multiple myeloma treatment through this clinical trial at a research site in Salt Lake City. Study-provided care at no cost to qualified participants.

Sponsored by University of Utah

Quick Self-Assessment

See if you qualify for this Salt Lake City location

Preparing your pre-screening questions…

Expert Care in Salt Lake City

Access smoldering multiple myeloma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related smoldering multiple myeloma treatment provided free

Apply for This Salt Lake City Location

Check if you qualify for this smoldering multiple myeloma clinical trial in Salt Lake City, UT

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Salt Lake City

    Convenient for UT residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Salt Lake City site if eligible
  4. 4Begin participation

About This Smoldering Multiple Myeloma Study in Salt Lake City

The purpose of this study is to define the natural history of high-risk smoldering myeloma in a modern cohort of patients undergoing close standard of care follow-up with diffusion weighted whole body magnetic resonance imaging.

Sponsor: University of Utah

Who Can Participate

Inclusion Criteria

Adult subject aged ≥ 18 years.
Diagnosis of smoldering myeloma as per the IMWG criteria, specifically:
Serum monoclonal protein (IgG or IgA) of 30g/L or greater per 24 hours or urinary monoclonal protein of 500mg or greater per 24 hours and/or
Clonal bone marrow plasma cells 10-59% with the absence of myeloma-defining events or amyloidosis
High-risk smoldering myeloma defined as two or more out of four of the following criteria:
M-spike greater than 2 g/dL
An involved/uninvolved free light chain ratio greater than 20
Bone marrow plasmacytosis greater than 20%
Presence of any of translocation (4;14), deletion 17p, deletion 13q or 1q gain by conventional cytogenetics/fluorescence in situ hybridization (FISH) studies) and/or
An IMWG SMM score of 9 or greater according to the IMWG risk model for smoldering multiple myeloma (SMM)
Diagnosis of high-risk SMM made within 365 days of enrollment in the study. Note: If a patient previously had MGUS or low/intermediate SMM- the date at which high-risk SMM was diagnosed would have to be within 365 days of enrollment in the study.

Exclusion Criteria

Presence of any features that would meet diagnostic criteria for myeloma as per the IMWG Criteria
Presence of extramedullary plasmacytomas
Presence of any focal bone marrow lesions, or lytic bone lesions on imaging done prior to screening or on screening. However, presence of diffuse or patchy infiltration of the marrow (without any clear lesions) on MRI, will not be an exclusion criteria. Patients with 1 focal marrow lesion on MRI that is attributable to plasma cell dyscrasia, will be excluded from study, even if they do not meet criteria for myeloma. Patients with 1 focal marrow lesion can only be enrolled if the lesion does not appear to be related to myeloma, based on the judgement of the investigator. Use of restricted diffusion and ADC values can assist in ascertainment.
Creatinine clearance of less than 40ml/min.
Presence of AL Amyloidosis (the amount of workup necessary to exclude AL Amyloidosis is per the discretion of the treating investigator, however the investigator must attest that they do not believe AL Amyloidosis to be present at time of enrollment. Serum nt-PROBNP is recommended as part of evaluation in order to ascertain for cardiac amyloidosis). Note: The Hgb cut-offs can vary between institutions (lower cut-off for Hgb University of Utah for men is a Hgb of 14.8, rendering a patient with Hgb of 12.7 as having a CRAB feature). If the Hgb is above 10g/dl but the patient meets the definition of anemia according to the IMWG criteria, by virtue of this being more than 2 g/dl below the limit of normal, the investigator can decide whether to call a patient being considered for screening as having multiple myeloma OR smoldering myeloma and allow enrollment on this study. Given that the values used to define high-risk SMM can change, at time of enrollment, if utilizing at least 2/4 of the 2/20/20+cytogenetics criteria to enroll, participants should meet at least 2/4 of the 2/20/20. If participants had met at least 2/4 previously at some timepoint but do not meet at least 2/4 currently, they cannot be enrolled in the study.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Salt Lake City?

Yes, this clinical trial (NCT06212323) has an active research site in Salt Lake City, UT that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Smoldering Multiple Myeloma Treatment Options in Salt Lake City, UT

If you're searching for smoldering multiple myeloma treatment options in Salt Lake City, UT, this clinical trial (NCT06212323) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Salt Lake City research site is actively enrolling participants for this clinical trial. You'll receive care from experienced smoldering multiple myeloma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all smoldering multiple myeloma clinical trials near you to find additional studies recruiting in your area.

More Multiple Myeloma Trials in Salt Lake City, UT

See all multiple myeloma clinical trials recruiting in Salt Lake City — not just this study.

Browse Multiple Myeloma Trials in Salt Lake City →

Browse More Trials by Condition

Multiple Myeloma TrialsAll Conditions →

Ready to Join in Salt Lake City?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Salt Lake City, UT